Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)

A Study of CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD).

Participants needed: 68
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: CRISPR TherapeuticsUpdated: Sep 30, 2026
Eligibility criteria

Age: ≥18 and ≤75 years. [+12]

Received augmentation therapy within the 6 weeks prior to CTX460 infusion [+17]

Read more
Status: Not yet recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive Multiple Sclerosis, relapsing Neuromyelitis Optica Spectrum Disorder, relapsing Myelin Oligodendrocyte Glycoprotein Antiody-Associated Disease, refractory AutoImmune Encephalitis, and refractory Stiff Person Syndrome

Participants needed: 220
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: CRISPR TherapeuticsUpdated: Sep 9, 2026
Eligibility criteria

Age ≥18 years and <70 years at screening. [+6]

Prior treatment with any gene therapy or genetically modified cell therapy. [+10]

Read more
Status: Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).

Participants needed: 80
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: CRISPR TherapeuticsUpdated: Aug 28, 2026Locations: 16
Eligibility criteria

Age ≥18 years and < 70 years of age. [+5]

Prior anti-CD19 therapy or any gene therapy/genetically modified cell therapy. [+12]

Read more